Rosmi

Adjunct to diet when response to diet & exercise is inadequate in patients w/ primary hypercholesterolaemia & mixed dyslipidaemia (including Fredrickson type IIa, IIb & heterozygous familial hypercholesterolemia); w/ primary dysbetalipoproteinaemia (Fredrickson type III hyperlipoproteinaemia). Patients w/ homozygous familial hypercholesterolaemia, either alone or as adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis). Primary prevention of CV disease in individuals w/o clinically evident CHD but w/ increased risk of CV disease based on age ≥50 yr in men & ≥60 yr in women, hsCRP ≥2 mg/L & presence of at least 1 additional CV disease risk factor (eg, HTN, low HDL-C, smoking or family history of premature CHD). Reduces risk of stroke, MI & arterial revascularization procedures. Adjunct to diet to reduce Total-C, LDL-C & ApoB levels in adolescents who are at least 1 yr postmenarche, 10-17 yr w/ heterozygous familial hypercholesterolaemia if after an adequate trial of diet therapy w/ LDL-C >190 mg/dL or >160 mg/dL & there is +ve family history of premature CVD or ≥2 other CVD risk factors.

Individualised dosage. Statin naïve patient & patient switched from another HMG-CoA reductase inhibitor 5-10 mg once daily. Severe hypercholesterolaemia at high CV risk May increase dose to 40 mg if treatment goal is not achieved on 20 mg. Childn Heterozygous familial hypercholesterolemia Initially 5 mg once daily. Max daily dose: 10 mg.

May be taken with or without food.

Hypersensitivity. Active liver disease or unexplained, persistent elevations of serum transaminases. Patients receiving concomitant cyclosporin. Severe renal impairment (CrCl <30 mL/min).

Dyslipidaemic Agents

C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

POM